An observational study in Major Depressive Disorder, sponsored by Alessio Fasano. Active, not recruiting at 1 site in Italy. Open to participants aged 14 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Alessio Fasano · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Depressive Disorder, Major with a site in Italy — 16 open to participants now, 18 under way, 6 of them phase 3. Depressive Disorder, Major · Italy.
Among the 50 studies in Depressive Disorder, Major with a site in Italy, this one is the 6th largest by planned enrollment of the 11 observational ones that give a count, is one of 4 that started in 2023, is one of 11 observational ones, reaches primary completion later than 9 of the 17 other live ones, and was the 39th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →16 of the 50 studies in Depressive Disorder, Major with a site in Italy are open now. Recruiting first, the newest first:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Sites in Italy, Germany, Spain
Ages up to 45 · Healthy volunteers
IRCCS Centro San Giovanni di Dio Fatebenefratelli · Sites in Italy
Ages 55–80
Janssen Research & Development, LLC · Sites in Italy, United States, Brazil and 4 more countries
Ages 12–17
IRCCS Centro San Giovanni di Dio Fatebenefratelli · Sites in Italy
Ages 50–80
Neurocrine Biosciences · Sites in Italy, United States, Australia and 8 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 14 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 132 across 403 observational studies indexed under Depressive Disorder, Major.
Median enrollment 348 across the 39 interventional studies, 350 across the 11 observational. Of the 29 that completed or were terminated, 15 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 50 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Alessio Fasano as lead sponsor.
Alessio Fasano has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
5 of the studies in Depressive Disorder, Major with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT06550037Alessio FasanoOptimize and Predict Antidepressant Efficacy for Patient With MDD Using Multi-omics Analysis and AI-predictive Tool | 2027-04 |
| NCT07009223IRCCS Centro San Giovanni di Dio FatebenefratelliLifestyle Interventions to Prevent Cognitive Deficits in Subjects With Depressive Symptoms: From Mechanisms to Clinical Practice | 2027-04 |
| NCT06990035IRCCS Centro San Giovanni di Dio FatebenefratelliImplementation of a Multiple Intervention to Promote Healthy Lifestyles in Patients With Depression | 2027-08 |
| NCT07932093Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoUnveiling Maternal-fetal BRAin-body Interactions in Pregnant WOmen Affected by Depression | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 50 studies in Depressive Disorder, Major with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
OPADE is a non-profit, observational, multicenter, open-label study aimed at defining personalized treatment for Major Depressive Disorder (MDD). In particular, we will combine genetics, epigenetics, microbiome, immune response data together with anamnesis, questionnaires, electroencephalography (EEG) collected from subjects suffering MDD. Eventually, an Artificial Intelligence (AI)/Machine Learning (ML) predictive tool will be created to guide clinicians in improving MDD treatment and patient's stratification.
Three hundred and fifty patients diagnosed with MDD will be enrolled for 24 months and divided into 4 groups according to age: 14-17 years (70 pediatric patients), 18-30 years (100 adult patients), 31-39 years (90 adult patients), 40-50 years (90 adult patients).
The study protocol includes 6 follow-up visits: T0 (enrollment), T1, T2, T3, T4, and T5. At each medical visit, psychometric questionnaires will be administered to the patients and contextual biological samples including blood, stool and saliva will be collected. The study will use a multi-omics approach including: metagenomic sequencing to characterize the microbiome composition; metabolomics to detect circulating metabolites; transcriptomics to quantify microRNAs; epigenomics to assess methylation variability between and within groups and immune assays to analyze the antibody immune response and inflammatory profiles (cytokines, interleukins and growth factors). Cortisol and lipoproteins will also be quantified. In parallel, cognitive assessment and emotional status will be recorded remotely by each patient via chatbot and wearable EEG devices, respectively. Specifically, the chatbot will collect patient's conversations and monitoring her/his feelings; the chat conversation will be than transformed in a machine-readable data. The EEG device is a mobile app that will also allows to associate brainwaves with patients' feelings.
Patients with Major Depressive Disorders
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
14-17 years (70 pediatric patients)
18-30 years (100 adult patients)
31-39 years (90 adult patients)
40-50 years (90 adult patients)
Identify neuroinflammatory indices
Several inflammatory markers such as G-CSF, GM-CSF, IFN-γ IL-10, IL-12p40, IL-15, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8/CXCL8, MCP-1/CCL2, TNF-α, TNFβ will be analysed.
Time frame: 2 years
Microbiome analysis
Identification of bacterial and fungal components.
Time frame: 2 years
Metabolomic analysis
The metabolomic analysis will involve three different groups of metabolites: 1) Intermediate of tryptophan metabolism (tryptophan, serotonin, 5-HIAA, quinurenin, quinurenic acid and other hormones and derivatives involved in the pathway) and others related to purines (paraxanthin/xanthin ratio); 2) L-acylcarnitines (including short chain, medium long-lasting acylcarnitine), with particular emphasis on laurylcarnitine and acetylcarnitine; 3) Phenolic (and related), such as phenolic acid, mandelic acid or methoxy-hydroxyphenyl glycol.
Time frame: 2 years
Analysis of lipoprotein profile
Different forms of lipoproteins will be evaluated: Apolipoproteins A1 and A2, HDL-apolipoproteins A1 and A2,free cholesterol HDL3, HDL3-apolipoprotein A1, HDL2-apolipoprotein A2, apolipoprotein A2, IDL, HDL-apolipoprotein A2, VLDL and its subtypes, VLDL2-triglycerides, VLDL3-triglyceridestriglycerides, VLDL2- cholesterol, VLDL3 cholesterol, VLDL4 cholesterol free of VLDL4, phospholipids VLDL2, Phospholipids VLDL3, Cholesterol LDL5, Cholesterol free LDL5, Phospholipids LDL5, LDL5-apolipoprotein B, HDL3 cholesterol, HDL4 cholesterol HDL4, HDL3 cholesterol free, free cholesterol HDL4, HDL3-phospholipids, HDL4-phospholipids, HDL3-apolipoprotein A1, HDL4-apolipoprotein A1, HDL3-apolipoprotein A2 and HDL4-apolipoprotein A2.
Time frame: 2 years
Identify immune-profile linked and epigenomic signatures
Methylome analysis on genomic DNA will be performed.
Time frame: 2 years
AI-powered diagnostics predictive tool (companion diagnostic-like)
Deploy an AI-powered predictive tool (companion diagnostic-like) in clinical practice for the prescription of anti-depressants. OPADE AI-powered predictive tool will be a class C medical device under the In vitro diagnostic classification.
Time frame: 2 years
Mood assessment through brain biomarker
Validate a patient tracking tool for mood assessment using brain biomarker.
Time frame: 2 years
Patient engagement digital tool
Validate a patient engagement digital tool that can be deployed in any patient community to enhance clinical study outcomes.
Time frame: 2 years
Discovery of a new set of biomarkers
Propose new set of biomarkers that can guide the development of new antidepressants
Time frame: 2 years
Investigation of the gut-brain-axis and of the biomarkers of interest in the context of mental diseases starting with MDD
Identify indices in MDD to improve diagnostic accuracy for primary prevention and patients' stratification.
Time frame: 2 years
Plan to share: Undecided
Started Aug 2023 (actual). Primary completion is estimated for Apr 2027, 44 months after the start.
Of 121 non-industry observational studies under Depressive Disorder, Major, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 73. This study's planned 44 months is close to that.
Counting every sponsor, half of 150 studies reached it within 38 months; a quarter within 21 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.